Skip to main content

TherapeuticsMD, Inc.

Data quality: 67%
TXMD
NASDAQ Manufacturing Chemicals
$2.05
▼ $0.03 (-1.59%)
6 months return
Momentum
Neutral
ROE
-2.08%

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-2.08%
Above sector avg (-54.47%)
ROIC-10.27%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio2.93
Interest Coverage-548.75

Valuation

P/E Ratio
-41.29 TTM
5.97 NTM
Below sector avg (-1.50)
P/B Ratio0.86
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Price History

Financial Trends

Analyst Price Target

No analyst coverage available

Earnings Surprises

EPS
Reported Estimate
Q32022 Q42022 Q12023 Q22023
Reported -$3.13 $8.23 -$0.24 -$0.24
Estimate -$2.04 -$1.11 $0.06 -$0.07
Surprise -53.43% +841.44% -500.00% -242.86%

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -2.08% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -569,000.0
ROE -2.08% ROA -1.47%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) N/A
ROIC -10.27% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2.93
Debt / Equity N/A Current Ratio 2.93
Interest Coverage -548.75 Asset Turnover N/A
Working Capital 9.56 M Tangible Book Value 23.53 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -41.29 · EV/EBITDA: N/A
P/E Ratio -41.29 Forward P/E 5.97
P/B Ratio 0.86 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield 16.75%
FCF Yield N/A
Market Cap 23.50 M Enterprise Value 23.50 M

Per Share

EPS: -0.05 · FCF/Share: N/A
EPS (Diluted TTM) -0.05 Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: N/A · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion N/A
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.76 M 1.30 M 69.96 M 86.95 M
Net Income -569,000.0 -2.18 M -10.28 M 112.00 M -172.42 M
EPS (Diluted) -0.05 -0.19 -0.98 11.96
Gross Profit 1.30 M 68.57 M 68.11 M
Operating Income -4.39 M -4.76 M -8.52 M 1.19 M -139.77 M
EBITDA
R&D Expenses 7.09 M
SG&A Expenses 4.74 M
D&A 384,000.0 509,000.0 922,000.0 1.19 M 4.09 M
Interest Expense 8,000.0 9,500.0 300,000.0 36.07 M 32.92 M
Income Tax -31,000.0 -31,000.0 -43,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 37.66 M 38.82 M 43.31 M 90.46 M 169.47 M
Total Liabilities 10.78 M 11.45 M 14.02 M 55.32 M 263.09 M
Shareholders' Equity 26.88 M 27.37 M 29.29 M 35.14 M -93.62 M
Total Debt 188.27 M 188.27 M
Cash & Equivalents 5.06 M
Current Assets 14.45 M 12.26 M 11.80 M 55.35 M 119.47 M
Current Liabilities 4.79 M 5.17 M 6.85 M 46.84 M 252.89 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -41.3 -1.5
P/B 0.9 1.6
ROE % -2.1 -54.5
Net Margin % -41.5
Rev Growth 5Y % 1.8
D/E 0.3

ETFs Holding This Stock

BRSIX BRSIX
0.03% weight
EMAAX EMAAX
0.00% weight
EMACX EMACX
0.00% weight
EAAAX EAAAX
0.00% weight
EMAYX EMAYX
0.00% weight
GADVX GADVX
0.00% weight
GABCX GABCX
0.00% weight